Zacks Research Has Optimistic Outlook of ESPR Q1 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Zacks Research boosted their Q1 2026 earnings estimates for shares of Esperion Therapeutics in a research note issued to investors on Monday, April 28th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings of ($0.19) per share for the quarter, up from their prior forecast of ($0.20). The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics' FY2026 earnings at ($0.40) EPS and Q1 2027 earnings at $0.03 EPS.

A number of other research firms also recently commented on ESPR. JMP Securities restated a "market outperform" rating and issued a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research report on Friday, April 25th. The Goldman Sachs Group decreased their price target on Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. Finally, Needham & Company LLC restated a "buy" rating and issued a $5.00 price target on shares of Esperion Therapeutics in a research note on Friday, April 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $6.42.

Esperion Therapeutics Trading Up 5.8 %

Shares of ESPR stock opened at $0.96 on Wednesday. The stock has a market cap of $190.20 million, a P/E ratio of -1.50 and a beta of 0.86. Esperion Therapeutics has a twelve month low of $0.82 and a twelve month high of $3.94. The stock has a 50 day moving average of $1.36 and a 200 day moving average of $1.94.

Hedge Funds Weigh In On Esperion Therapeutics

Hedge funds have recently modified their holdings of the stock. Synergy Asset Management LLC lifted its holdings in shares of Esperion Therapeutics by 3,496.3% during the first quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 30,138 shares during the last quarter. Mackenzie Financial Corp increased its stake in shares of Esperion Therapeutics by 116.1% in the fourth quarter. Mackenzie Financial Corp now owns 143,252 shares of the biopharmaceutical company's stock valued at $315,000 after buying an additional 76,965 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of Esperion Therapeutics by 0.4% during the fourth quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company's stock worth $7,956,000 after purchasing an additional 16,100 shares in the last quarter. Rafferty Asset Management LLC acquired a new stake in shares of Esperion Therapeutics in the 4th quarter valued at $82,000. Finally, ProShare Advisors LLC boosted its position in shares of Esperion Therapeutics by 75.2% in the 4th quarter. ProShare Advisors LLC now owns 62,549 shares of the biopharmaceutical company's stock worth $138,000 after purchasing an additional 26,843 shares during the last quarter. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.